Modern CNS Drug Discovery
portes grátis
Modern CNS Drug Discovery
Reinventing the Treatment of Psychiatric and Neurological Disorders
Schreiber, Rudy
Springer Nature Switzerland AG
06/2021
283
Dura
Inglês
9783030623500
15 a 20 dias
765
Descrição não disponível.
PART I - Introduction.- Innovator, Entrepreneur, Leader: The Tripartite Drug Discovery Neuroscientist.- PART II - Innovation in the Discovery of Novel Therapeutic Approaches.- Drug Discovery in CNS: Finding a Target for What?.- Neurogenomics with Application to Schizophrenia and Other Major Neuropsychiatric Diseases with Complex Heredity.- Epigenetics in Drug Discovery: Achievements and Challenges.- Conventional Behavioral Models and Readouts in Drug Discovery: The Importance of Improving Translation.- Safety and Drug Metabolism: Toward NCE and First in Human.- The Various Forms of Non-invasive Brain Stimulation and Their Clinical Relevance.- Is Non-invasive Brain Stimulation the Low-Hanging Fruit?.- PART III - Translational Medicine and Technology.- Electrophysiology: From Molecule to Cognition, from Animal to Human.- MRI in CNS Drug Development.- Positron Emission Tomography in Drug Development.- Application of Cognitive Test Outcomes for Clinical Drug Development.- Exciting Research in the Field of Sexual Psychopharmacology: Treating Patients with Inside Information.- A Paradigm Shift from DSM-5 to Research Domain Criteria: Application to Translational CNS Drug Development.- PART IV - Clinical Development and Regulatory Approval.- The Special Challenges of Developing CNS Drugs.- Phase 1 Clinical Trials in Psychopharmacology.- Early Development of Erenumab for Migraine Prophylaxis.- Microdosing Psychedelics as a Promising New Pharmacotherapeutic.- Partnering with the FDA.
Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.
drug development;drug screening;Neurological Disorders;pharmaceutical industry;drug development pipeline;Biomarkers;clinical trials;Drug Discovery;Brain Imaging;Clinical Development;Central Nervous System;Neuroinformatics;Novel Therapeutics;Psychopharmacology;Psychiatric Disorders
PART I - Introduction.- Innovator, Entrepreneur, Leader: The Tripartite Drug Discovery Neuroscientist.- PART II - Innovation in the Discovery of Novel Therapeutic Approaches.- Drug Discovery in CNS: Finding a Target for What?.- Neurogenomics with Application to Schizophrenia and Other Major Neuropsychiatric Diseases with Complex Heredity.- Epigenetics in Drug Discovery: Achievements and Challenges.- Conventional Behavioral Models and Readouts in Drug Discovery: The Importance of Improving Translation.- Safety and Drug Metabolism: Toward NCE and First in Human.- The Various Forms of Non-invasive Brain Stimulation and Their Clinical Relevance.- Is Non-invasive Brain Stimulation the Low-Hanging Fruit?.- PART III - Translational Medicine and Technology.- Electrophysiology: From Molecule to Cognition, from Animal to Human.- MRI in CNS Drug Development.- Positron Emission Tomography in Drug Development.- Application of Cognitive Test Outcomes for Clinical Drug Development.- Exciting Research in the Field of Sexual Psychopharmacology: Treating Patients with Inside Information.- A Paradigm Shift from DSM-5 to Research Domain Criteria: Application to Translational CNS Drug Development.- PART IV - Clinical Development and Regulatory Approval.- The Special Challenges of Developing CNS Drugs.- Phase 1 Clinical Trials in Psychopharmacology.- Early Development of Erenumab for Migraine Prophylaxis.- Microdosing Psychedelics as a Promising New Pharmacotherapeutic.- Partnering with the FDA.
Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.
